Polyethylene Glycol

is prescribed to treat:

• Constipation • Various related conditions in the gastrointestinal category • Associated symptoms and complications

It is an important medication that helps manage these conditions effectively.

Polyethylene glycol 3350 (MiraLAX, GlycoLax) is an osmotic laxative used for occasional constipation, chronic constipation, and bowel preparation before colonoscopy. It is available over the counter, is among the best-evidenced laxatives available, and is the agent most guidelines reach for first.

Mechanism of Action

Polyethylene glycol 3350 is a large, inert, water-soluble polymer that is not absorbed from the gastrointestinal tract and not metabolised by gut bacteria. It works by pure osmosis: the polymer holds water within the intestinal lumen through hydrogen bonding, increasing stool water content.

Softer, bulkier stool distends the colon, which stimulates normal propulsive motility. The drug does not act on the bowel wall, does not stimulate nerve endings, and does not alter electrolyte transport — which is what separates it from stimulant laxatives such as senna and bisacodyl, and from osmotic agents such as lactulose that are fermented by colonic bacteria and produce gas and bloating.

Because it is neither absorbed nor fermented, polyethylene glycol causes markedly less cramping, gas, and bloating than most alternatives. It also does not cause the electrolyte disturbance associated with magnesium- and phosphate-based osmotics, which matters considerably in kidney impairment and in older adults.

The particle size is large enough that systemic absorption is negligible, which is why it is considered safe for long-term use — including in children — where stimulant laxatives raise more concern.

Clinical Use

Polyethylene glycol is first-line for chronic constipation in adults and children, with better evidence for efficacy and tolerability than lactulose, and a better side-effect profile than stimulants.

Onset is not immediate. It typically takes one to three days to produce an effect, and patients expecting overnight relief conclude it does not work and either stop or add a stimulant. Saying this in advance prevents most of that.

Dose is titrated to effect rather than fixed: the goal is soft, formed, comfortably passed stool, and the dose is adjusted up or down toward that. This is worth stating explicitly, because patients often take a standard dose indefinitely regardless of result.

The old fear that laxative use causes dependence or a lazy bowel applies mainly to long-term stimulant use, and even there the evidence is weaker than the belief. For polyethylene glycol there is no such concern — it does not act on the bowel wall at all — and patients with genuine chronic constipation should not be rationing an effective treatment out of misplaced worry.

Fibre is often recommended first, and it helps some patients, but it worsens symptoms in slow-transit constipation and in defecatory disorders. Increasing fibre in a patient who is already bloated and not emptying can make matters considerably worse. The chronic constipation article covers why fibre and water alone frequently fail, and our gastrointestinal team manages constipation that is not responding.

When Constipation Needs Investigation Rather Than Treatment

Not all constipation is primary, and treating it symptomatically without asking why can delay an important diagnosis.

New-onset constipation in an adult over 50, particularly with weight loss, rectal bleeding, iron deficiency anemia, or a change in stool calibre, warrants colonoscopy rather than a laxative. Colorectal cancer presenting as altered bowel habit is exactly the scenario that empiric treatment obscures.

Secondary causes are common and correctable: hypothyroidism, hypercalcemia, diabetes, and — most often — medications. Opioids such as oxycodone, anticholinergics, calcium channel blockers, iron, and ondansetron all cause constipation, and reviewing the medication list frequently identifies the cause.

Defecatory disorders — pelvic floor dyssynergia, in which the pelvic floor fails to relax during defecation — do not respond well to laxatives of any kind and are treated with pelvic floor biofeedback. Patients describing straining, incomplete evacuation, or needing to assist manually should be evaluated for this rather than escalated through laxatives. The MedlinePlus polyethylene glycol entry covers prescribing detail, and the NIDDK constipation resource covers evaluation.

Monitoring and Follow-Up

No laboratory monitoring is required for ordinary use, which is one of its advantages over magnesium- and phosphate-containing alternatives.

What should be monitored is response and whether the underlying cause has been addressed. Persistent constipation despite adequate polyethylene glycol at a titrated dose is a reason for evaluation, not for adding successive agents.

For opioid-induced constipation specifically, polyethylene glycol combined with a stimulant is the usual approach, and it should be started with the opioid rather than after constipation develops. Where that fails, peripherally acting mu-opioid receptor antagonists address the mechanism directly.

In bowel preparation for colonoscopy, larger volumes of a balanced electrolyte polyethylene glycol solution are used — a different product and a different purpose from daily use of the powder.

Special Populations

In children, polyethylene glycol is first-line for functional constipation and is used for extended periods, including for disimpaction, with a strong safety record. Concerns raised about neuropsychiatric effects in children have not been substantiated by subsequent investigation.

In older adults it is preferred over magnesium- and phosphate-based osmotics, which cause electrolyte disturbance and can precipitate kidney injury. In kidney impairment it is likewise the safer choice for the same reason.

In pregnancy it is considered acceptable and is commonly used, since constipation is very common and systemic absorption is negligible. It is contraindicated in known or suspected bowel obstruction, and significant abdominal pain, distension, or vomiting should be evaluated before any laxative is given.

When to Contact Your Doctor

Seek prompt evaluation for severe abdominal pain, marked distension, vomiting, or inability to pass gas, which may indicate obstruction — do not take a laxative in that situation.

Report rectal bleeding, black stools, unintended weight loss, or a persistent change in bowel habit, particularly if you are over 50. Report constipation that does not respond to an adequately titrated dose.

Report straining, a sense of incomplete emptying, or needing to assist manually, which suggests a pelvic floor problem that laxatives will not fix. If you started a new medication around the time constipation began, mention it — that is frequently the answer.

To evaluate constipation that is not responding, review medications that may be causing it, or discuss whether investigation is needed, contact us or schedule a visit.